PDCD1 and neoplasm: Studies have identified strong expression of immune checkpoint ligands in this type of tumor microenvironment, including PD-1 (25), which accounts for the higher sensitivity and superior efficacy of PD-1 inhibitors in dMMR/MSI-H tumors (26).